Research Corporation Technologies is a venture capital firm specializing in start up and early-stage companies. It is a technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production. With medical devices, it invests in preclinical and early clinical candidate interventional medical devices, preclinical and early clinical candidate temporary or permanent indwelling devices, devices that address unmet medical needs and offer significant clinical benefits over existing ...
5210 East Williams Circle
Tucson, AZ 85711-4410
Founded in 1987
Research Corporation Technologies and BioGrammatics Announce their Partnership to Commercialize and Distribute Pichia GlycoSwitch
Jun 4 13
Research Corporation Technologies and BioGrammatics Inc. announced their partnership to commercialize and distribute Pichia GlycoSwitch (R) -- a new expression system to modify the glycosylation of recombinant proteins in the yeast Pichia pastoris. Pichia GlycoSwitch(R) adds to the advantages of using Pichia pastoris as a host for the production of recombinant proteins with increased flexibility over protein glycosylation (the addition of sugars to a protein of interest). Under the partnership, BioGrammatics will provide expression system kits and services; RCT will oversee commercial licensing programs.
Lucigen Corporation and Research Corporation Technologies Announce Partnership and Launch Endotoxin-free CleanColi™ Expression System
May 1 13
Lucigen Corporation and Research Corporation Technologies (RCT) announced a partnership to commercialize and distribute the CleanColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin. Lucigen will produce and sell kits containing CleanColi™ competent cells and provide contract research services for the CleanColi™ Expression System. Lucigen simultaneously announces the release of a CleanColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the CleanColi™ commercial licensing programs. Drug discovery researchers are increasingly turning to biologics as the source for new therapeutics, utilizing the incredible diversity of proteins in order to find new treatments for disease. To synthesize and manipulate these proteins, researchers normally insert genes coding for the desired protein into mammalian, yeast, or bacterial cells. The common bacteria E. coli is a widely used system for expression of recombinant proteins, but this method has the disadvantage that, without time-consuming and expensive cleanup, it produces contaminating endotoxin that kills human cells. Failure to remove endotoxin from the final product can result in false or misleading results, potentially causing a researcher to improperly reject a promising drug candidate. Lucigen and RCT have developed the CleanColi™ competent cell strain for protein expression. This new strain has a genetically modified lipopolysaccharide (LPS) that does not cause an endotoxic response in human cells. By producing proteins without contaminating endotoxin, researchers can increase productivity by reducing the time, cost, and loss of product associated with endotoxin removal. More important, cell-based assays can be performed without concern that LPS (endotoxin) contamination could be masking promising results. Researchers can accelerate drug discovery research and ensure the most accurate results possible. Additional cell lines for plasmid production and phage display are also planned for release, creating a complete system for scientists to study a large variety of biologic compounds for therapeutic applications.